Reported Earlier, Eisai And Biogen Reveal Five-Year Findings On Alzheimer's Treatment Lecanemab At Clinical Trials for Alzheimer's Disease Conference
Biogen Inc. -1.43% Pre
Biogen Inc. BIIB | 174.40 175.06 | -1.43% +0.38% Pre |
New testing method highlights link between protofibrils and biomarkers for neurodegeneration-
-Patient and caregiver perspectives on five-year treatment with lecanemab -
- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD-